VAM
ACAD icon

Visium Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Visium Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-79,300
Closed -$2.57M – 1
2016
Q2 		$2.57M Buy
+79,300
New +$2.65M 0.18% 151

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Visium Asset Management's ACAD Position: Q2 2016 in Review

Visium Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2016, closing a stake of 52,700 shares — an estimated $1.76M sold.

Visium Asset Management first reported a position in ACAD in Q2 2013 and held it in 8 quarters. The position peaked at $36.8M in Q2 2013. 228 funds tracked by Wall St. Rank hold ACAD as of Q2 2016.

  • Visium Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Visium Asset Management sold 52,700 Acadia Pharmaceuticals shares in Q2 2016, an estimated $1.76M.
  • Visium Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Visium Asset Management's Acadia Pharmaceuticals position peaked at $36.8M in Q2 2013.
  • 228 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.